Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 19/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 12/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7334148 | 0.88 | F2 (0.58) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL4432108 | 0.83 | F2 (0.77) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL951515 | 0.82 | CASP1 (0.48) | F2PRSS1PRSS2PRSS3CASP1 | |
| SCHEMBL950528 | 0.78 | CASP1 (0.70) | F2PRSS1CASP1 | |
| SCHEMBL6285572 | 0.76 | F2 (0.50) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7233400 | 0.76 | F2 (0.57) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL2801889 | 0.75 | ELANE (0.65) | F2PRSS1CASP1 | |
| SCHEMBL7340767 | 0.75 | F2 (0.58) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL5117233 | 0.75 | F2 (0.58) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL4456640 | 0.74 | ALDH1A1 (0.44) | CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165062-A1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-07-28 | — | — | US | disclosed |
| US-6870056-B1 | Substitituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-03-22 | — | — | US | disclosed |
| US-6867217-B1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-03-15 | — | — | US | disclosed |
| WO-2001087842-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165062-A1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, TFPI2 | F2 6/4885PRSS1 10/4885PRSS2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.